Role of statins in the management of dyslipidemia after cardiac transplant: Randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin

Journal of Heart and Lung Transplantation

Volumn 19, Issue 7, 2000, Pages 710-715

  Magnani, Gaia ^a   Carinci, Valeria ^a   Magelli, Carlo ^a   Potena, Luciano ^a   Reggiani, Letizia Bacchi ^a   Branzi, Angelo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; AZATHIOPRINE; CHOLESTEROL; CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; PRAVASTATIN; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; LIPID BLOOD LEVEL; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CREATINE KINASE; FEMALE; HEART TRANSPLANTATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PRAVASTATIN; PYRROLES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0033877290     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(00)00128-5     Document Type: Article

References (17)

1. Miller L.W., Schlant R.C., Kobashigawa J., et al. Task force 5 complications. J Am Coll Cardiol. 22:1993;41-54.
2. Keogh A.M., Valantine H.A., Hunt S.A. Impact of proximal or midvessel discrete coronary artery disease on survival after heart transplantation. J Heart Lung Trasplant. 11:1992;892-901.
3. Norman D.J., Illingworth D.R., Munson J., et al. Myolisis and acute renal failure in a heart transplant recipent receiving lovastatin. (letter) N Engl J Med. 318:1988;46-47.
4. Jones P., Kafonek S., Laurora I., et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia. Am J Cardiol. 82:(1):1998;128.
5. Grattan M.T., Moreno-Cabral C.E., Starnes V.A., et al. Eight years results of cyclosporine treated patients with cardiac transplant. J Thorac Cardiovasc Surg. 99:1990;500-509.
6. Billingham M.E. Pathology and etiology of chronic rejection of the heart. Clin Transplant. 8:1994;289-292.
7. Anderson H.O. Heart allograft vascular disease an obliterative vascular disease in transplanted hearts. Atherosclerosis. 142:1999;243-262.
8. McManus B.M., Horley K.J., Wilson J.E., et al. Prominence of coronary arterial wall lipids in human heart allografts. Implications for pathogenesis of allograft arteriopathy. Am J Pathol. 147:1995;293-308.
9. Eich D., Thompson J.A., Ko D.J., et al. Hypercholesterolemia in long term survivors of heart transplantation an early marker of accelerated coronary artery disease. J Heart Lung Transplant. 10:1991;45-49.
10. Miller L., Kobagashigawa J., Valantine H., et al. The impact of cyclosporine dose and level on the development and progression of allograft coronary disease. J Heart Lung Transplant. 65:1998;661-667.
11. Hosenpud J.T., Bennett L.E., Keck B.M., et al. The Registry of the international Sociery for Heart and Lung Transplantation sixteenth official report - 1999. J Heart Lung Transplant. 18:1999;611-626.
12. Renlund D.G., Bristow M.R., Crandall B.G., et al. Hypercholesterolemia after heart transplantation. Amelioration by corticosteroisd-free maintenance immunosoppression. J Heart Lung Transplant. 8:1989;214-219.
13. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 333:1995;621-627.
14. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. Circulation. 96:1997;1398-1402.
15. Katznelson S., Kobagashigawa J.A. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation lipid lowering and immunosuppression. Kidney Int Suppl. 52:1995;112-115.
16. Katznelson S. Immunosuppressive and antiproliferative effects of HMG-CoA reductase inhibitors. Transplant Proc. 31:(suppl B):1999;22S-24S.
17. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.